Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan Cancer Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Hongxia Wang) · whx365@126.com · +8621-38196379
Contact: Study coordinator (Ting Li) · cinderellaliting@126.com · +86-18121299346
Contact: Principal Investigator (Hongxia Wang, Chief physician)

Study leads

Hongxia Wang, Chief physician
Principal Investigator
Fudan University Principal Investigator Biyun Wang , Chief physician Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Mobile, United States

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

DCIS · Breast Cancer · Breast Neoplasms

Abroad (travel likely)RecruitingPHASE3

Houston, United States · Hong Kong, Hong Kong

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Beijing, China

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

IsraelRecruitingPHASE3

Daphne, United States · Auburn, United States